On September 14, 2026, Armata Pharmaceuticals, Inc. (NYSE American: ARMP) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to AP-SA02. The designation applies to the intravenously administered multi-phage product candidate for the adjunct treatment of complicated bacteremia caused by methicillin-sensitive Staphylococcus aureus (MSSA) or methicillin-resistant S. aureus (MRSA).
According to the company, the designation is supported by data from the Phase 1b/2a diSArm study. The study evaluated AP-SA02 in adults with complicated S. aureus bacteremia (SAB). The proprietary purification process enabled a dosing regimen of intravenous administration every six hours for five days. The company reported that this regimen was well tolerated with no serious adverse events attributed to AP-SA02.
Results from the study indicated that when AP-SA02 was added to best available antibiotic therapy (BAT), it demonstrated higher and earlier clinical cure rates than placebo plus BAT. At the end-of-study assessment, 28 days after completion of BAT, 100% of patients treated with AP-SA02 maintained a clinical response without relapse, compared to 75% of patients receiving placebo. Additionally, patients treated with AP-SA02 showed favorable trends in biomarkers, including more rapid normalization of C-reactive protein (CRP) and Interleukin-10 (IL-10).
Dr. Deborah Birx, Chief Executive Officer of Armata, stated that the designation, combined with Qualified Infectious Disease Product (QIDP) and Fast Track designations, recognizes the urgent need for new treatment options for complicated SAB. The company plans to advance AP-SA02 into a Phase 3 superiority study in complicated SAB, anticipated to initiate in the second half of 2026. The Phase 1b/2a development of AP-SA02 is partially supported by a $28.7 million Department of War award received through the Medical Technology Enterprise Consortium (MTEC).
